Daito Pharmaceutical Co.,Ltd.
Financial Results Explanation Document
For the fiscal year ending May 2026, consolidated sales are forecasted to be 50,650 million yen (YoY +0.0%), with operating income at 3,637 million yen (up 38.8%). Increased research and development expenses and capital investments are expected to improve profit margins, generating high expectations for future business expansion.
AI要約
Performance Overview
For the fiscal year ending May 2026, consolidated sales are stable at 50,650 million yen (YoY +0.0%), while operating income significantly increased by 38.8% to 3,637 million yen. Increased research and development expenses and capital investments are expected to enhance profit margins, fostering optimism for future business expansion. The sales composition has diversified to include pharmaceuticals and health foods, maintaining a stable revenue base.
Future Outlook and Impact on Investors
The company plans to continue investing in research and development and capital expenditures, expanding new drugs and businesses. It aims to improve profit margins while maintaining shareholder returns and dividend policies, focusing on long-term growth. Investors can expect profit growth and stable dividends.
Daito Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
